دورية أكاديمية
أعرض في EDS

Therapeutic efficacy of milbemycin oxime/praziquantel oral formulation (Milbemax®) against Thelazia callipaeda in naturally infested dogs and cats.

التفاصيل البيبلوغرافية
العنوان: Therapeutic efficacy of milbemycin oxime/praziquantel oral formulation (Milbemax®) against Thelazia callipaeda in naturally infested dogs and cats.
المؤلفون: Motta B; Institute of Parasitology, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 266a, Zurich, Switzerland., Schnyder M, Basano FS, Nägeli F, Nägeli C, Schiessl B, Mallia E, Lia RP, Dantas-Torres F, Otranto D
المصدر: Parasites & vectors [Parasit Vectors] 2012 May 19; Vol. 5, pp. 85. Date of Electronic Publication: 2012 May 19.
نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101462774 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-3305 (Electronic) Linking ISSN: 17563305 NLM ISO Abbreviation: Parasit Vectors Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central
مواضيع طبية MeSH: Anthelmintics/*administration & dosage , Cat Diseases/*drug therapy , Dog Diseases/*drug therapy , Macrolides/*administration & dosage , Praziquantel/*administration & dosage , Spirurida Infections/*veterinary , Thelazioidea/*isolation & purification, Administration, Oral ; Animals ; Cat Diseases/parasitology ; Cats ; Conjunctiva/parasitology ; Dog Diseases/parasitology ; Dogs ; Drug Therapy, Combination ; Female ; Italy ; Male ; Placebos/administration & dosage ; Spirurida Infections/drug therapy ; Switzerland ; Treatment Outcome
مستخلص: Background: Over the last few decades, canine and feline thelaziosis caused by Thelazia callipaeda eye worms has gained the attention of the veterinary community due to the spread of this ocular infestation in geographical areas previously regarded as non endemic. The therapeutic efficacy of milbemycin oxime/praziquantel tablets (Milbemax®) against T. callipaeda was tested in naturally infested dogs and cats.
Methods: From January 2009 to July 2011 a placebo controlled and randomized field study was conducted in T. callipaeda endemic areas of Switzerland (CH) and Italy (ITA) involving client-owned animals. Dogs (n = 56) and cats (n = 31) were physically examined at enrolment Day 0 (D0) and twice afterwards (D7 and D14). Infested animals were orally treated with Milbemax® or with placebo tablets on D0 and, if an animal was found still infested with T. callipaeda, also on D7. On D14 nematodes were flushed from the conjunctiva, identified and counted.
Results: Out of 56 dogs, 43 were included in the statistical analysis, whereas 13 were excluded because the products under investigation were not administered with food, as required by the label. On D7 and D14, 72.7% and 90.9% of treated dogs were eye worm free, whereas in the placebo group 95.2% and 76.2% still harbored nematodes, resulting in a mean percentage worm count reduction for the Milbemax® group of 86.1% and 96.8%, respectively. Both results were significantly higher (p = 0.0001) than the placebo group. Out of the 31 cats included in the study at D7 and D14, 53.3% and 73.3% treated with Milbemax® were free of T. callipaeda, while 81.3% and 73.3 in the placebo group were still harbouring eye worms, resulting in a mean percentage worm count reduction for the treated group of 62.2% and 80.0%, respectively. Both results were significantly higher (p = 0.0106 and p = 0.0043) than the placebo group.
Conclusions: The commercial formulation of milbemycin oxime at the minimal dose of 0.5 mg/kg and 2 mg/k in dogs and cats, respectively, showed a high therapeutic efficacy in curing T. callipaeda infestations. The advantages of an oral application are additionally increased by the large spectrum of activity of praziquantel and milbemycin oxime against Cestodes and Nematodes infesting dogs and cats.
References: Parasitology. 2004 Nov;129(Pt 5):627-33. (PMID: 15552407)
Vet Rec. 2004 May 1;154(18):568-9. (PMID: 15144004)
Vet Rec. 2004 Jan 31;154(5):143-5. (PMID: 14979443)
Vet Rec. 2007 Dec 15;161(24):820-1. (PMID: 18083983)
Parasit Vectors. 2011 Jul 27;4:148. (PMID: 21791108)
Vet Parasitol. 2003 Oct 30;116(4):315-25. (PMID: 14580802)
Trans R Soc Trop Med Hyg. 1988;82(4):627. (PMID: 3256118)
Parasit Vectors. 2011 Mar 23;4:41. (PMID: 21429191)
Vet Parasitol. 2008 Nov 7;157(3-4):321-7. (PMID: 18774229)
Parasitol Res. 2010 Feb;106(3):715-7. (PMID: 19937259)
Vet Parasitol. 2005 Apr 20;129(1-2):89-93. (PMID: 15817208)
Am J Trop Med Hyg. 1970 May;19(3):476-9. (PMID: 5463089)
Emerg Infect Dis. 2008 Apr;14(4):647-9. (PMID: 18394285)
Med Vet Entomol. 2006 Dec;20(4):358-64. (PMID: 17199746)
Vet Parasitol. 2008 Jul 4;154(3-4):351-3. (PMID: 18456409)
Vet Parasitol. 2009 Dec 23;166(3-4):262-7. (PMID: 19782474)
Emerg Infect Dis. 2010 Dec;16(12):1943-5. (PMID: 21122226)
Vet Parasitol. 2007 Nov 10;149(3-4):294-7. (PMID: 17854998)
Br J Ophthalmol. 2000 Apr;84(4):441. (PMID: 10777285)
Parasitology. 2005 Dec;131(Pt 6):847-55. (PMID: 16336738)
المشرفين على المادة: 0 (Anthelmintics)
0 (Macrolides)
0 (Placebos)
0502PUN0GT (milbemycin oxime)
6490C9U457 (Praziquantel)
تواريخ الأحداث: Date Created: 20120501 Date Completed: 20120912 Latest Revision: 20211021
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC3356600
DOI: 10.1186/1756-3305-5-85
PMID: 22541136
قاعدة البيانات: MEDLINE
الوصف
تدمد:1756-3305
DOI:10.1186/1756-3305-5-85